Merz’ IncobotulinumtoxinA Begins Phase 3 MINT Trials for Migraine Prevention
Written by
Neurology Live
Published
0
comments
0
min
Merz initiates phase 3 trials for Xeomin, targeting migraine prevention in adults, aiming to fill gaps in current treatment options.